Sirirat Naemkhunthot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sirirat Naemkhunthot has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Areerat Sa-Ngarsang
National Institute of Health, Department of Medical Science, Ministry of Public Health, Nonthaburi 11000, Thailand
1 shared publication - Chika Tanaka
VisGene Ltd., Osaka 562-0033, Japan
1 shared publication - Emi. E. Nakayama
Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Japan
1 shared publication - Juthamas Phadungsombat
Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
1 shared publication - Katsuya Ogata
VisGene Ltd., Osaka 562-0033, Japan
1 shared publication - Kunihiro Kaihatsu
VisGene Ltd., Osaka 562-0033, Japan
1 shared publication
Latest Publications
- Open Access
- 7 December 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (12) , 802
An Improved Dengue Virus Serotype-Specific Non-Structural Protein 1 Capture Immunochromatography Method with Reduced Sample Volume
The four serotypes of dengue virus (DENV), types 1 to 4 (DENV-1 to DENV-4), exhibit approximately 60% identity in the encoded amino acid residues of viral proteins. Reverse transcription of RNA extracted from patient serum specimens followed by PCR amplification with serotype-specific probes is the current standard technique for DENV serotyping. However, this method is time- and cost-consuming, and rapid detection systems with low cost are desirable. Previously, we developed a prototype serotype-specific immunochromatography system. That system was composed of four strips with four corresponding distinct sample buffers, each specifically detecting a single DENV serotype. In the present study, we improved this system by combining pairs of strips into one lateral-flow cassette each, providing DENV-1 and DENV-2 detection in one device and DENV-3 and DENV-4 detection in a second device; this strategy successfully reduced the required sample volume. Furthermore, we were able to adjust the composition of the sample buffers such that a single sample buffer sufficed for all four DENV serotype detection reactions, allowing much easier handling of the devices. Evaluation of this new device against laboratory and clinical DENV isolates and clinical specimens from DENV-infected individuals showed sensitivity that was comparable to that of our previous version, yielding serotype specificity of 100%. These new devices are expected to be of use in the clinical setting, accelerating both prospective and retrospective epidemiological studies.
- 7 December 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (12) , 802
Open AccessAn Improved Dengue Virus Serotype-Specific Non-Structural Protein 1 Capture Immunochromatography Method with Reduced Sample Volume
The four serotypes of dengue virus (DENV), types 1 to 4 (DENV-1 to DENV-4), exhibit approximately 60% identity in the encoded amino acid residues of viral proteins. Reverse transcription of RNA extracted from patient serum specimens followed by PCR amplification with serotype-specific probes is the current standard technique for DENV serotyping. However, this method is time- and cost-consuming, and rapid detection systems with low cost are desirable. Previously, we developed a prototype serotype-specific immunochromatography system. That system was composed of four strips with four corresponding distinct sample buffers, each specifically detecting a single DENV serotype. In the present study, we improved this system by combining pairs of strips into one lateral-flow cassette each, providing DENV-1 and DENV-2 detection in one device and DENV-3 and DENV-4 detection in a second device; this strategy successfully reduced the required sample volume. Furthermore, we were able to adjust the composition of the sample buffers such that a single sample buffer sufficed for all four DENV serotype detection reactions, allowing much easier handling of the devices. Evaluation of this new device against laboratory and clinical DENV isolates and clinical specimens from DENV-infected individuals showed sensitivity that was comparable to that of our previous version, yielding serotype specificity of 100%. These new devices are expected to be of use in the clinical setting, accelerating both prospective and retrospective epidemiological studies.